On April 30, 2014, IsoRay, Inc. (NYSEMKT:ISR), announced the publication of the first major peer reviewed study showing improved results using IsoRay’s Cesium-131 seeds in the treatment of gynecologic cancer. IsoRay, Inc. (NYSEMKT:ISR), shares after opening at $2.17 moved to $2.34 on last trade day and at the end of the day closed at $2.24. Company price to sales ratio in past twelve months was calculated as 26.29 and price to cash ratio as 27.49. IsoRay, Inc. (NYSEMKT:ISR), showed a positive weekly performance of 2.75%.
LiveDeal Inc (NASDAQ:LIVE), continues to be just what the restaurant industry ordered. Business owners find the company’s unique real-time online/mobile deal engine to be a value added solution to driving customers to their doors when they most need them. LiveDeal Inc (NASDAQ:LIVE), shares advanced 5.66% in last trading session and ended the day on $4.85. LiveDeal Inc (NASDAQ:LIVE), return on equity ratio is recorded as -205.00% and its return on assets is -159.00%. LiveDeal Inc (NASDAQ:LIVE), yearly performance is 40.14%.
General Moly, Inc. (NYSEMKT:GMO), was the recipient of a significant growth in short interest in January. As of April 15th, there was short interest totalling 4,477,469 shares, a growth of 13.5% from the March 31st total of 3,943,201 shares, Analyst Ratings Net reports. General Moly, Inc. (NYSEMKT:GMO), shares moved up 5.50% in last trading session and was closed at $1.15, while trading in range of $ 1.11 – 1.16. General Moly, Inc. (NYSEMKT:GMO), year to date (YTD) performance is -14.48%.
On April 30, 2014, Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of InspireMD Inc (NYSEMKT:NSPR). The investigation concerns possible violations of federal securities laws, and focuses on the Company’s operations and financial prospects. InspireMD Inc (NYSEMKT:NSPR), weekly performance is -6.08%. On last trading day company shares ended up $2.16. InspireMD Inc (NYSEMKT:NSPR), distance from 50-day simple moving average (SMA50) is -28.07%. Analysts mean target Price for the company is $6.00.